Oncology & Rare Diseases Archives

Healthcare Quality, Patient Safety & Policy

Revolution, Summit to Test RAS(ON) Drugs with Ivonescimab

Business WireJune 30, 2025August 1, 2025

by Business WireJune 30, 2025August 1, 20250118

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a...

Workforce Development & Leadership

STORM Therapeutics Names Dr. Eric Martin as Chief Development Officer

PR NewswireJune 27, 2025August 1, 2025

by PR NewswireJune 27, 2025August 1, 20250122

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist...

Clinical Research, Pharma & Healthcare Financing

Innovent Presents Phase 3 DREAMS-1 Study of Mazdutide at ADA 85th

PR NewswireJune 25, 2025August 1, 2025

by PR NewswireJune 25, 2025August 1, 20250155

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...

Clinical Research, Pharma & Healthcare Financing

Simcere Zaiming Doses First US Patient in SIM0500 Phase 1 Trial

PR NewswireJune 19, 2025August 1, 2025

by PR NewswireJune 19, 2025August 1, 20250135

Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1...

Clinical Research, Pharma & Healthcare Financing

TFS HealthScience expands collaboration with Oncomatryx for OMTX705 trial

PR NewswireMay 6, 2025August 1, 2025

by PR NewswireMay 6, 2025August 1, 20250174

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting...

Tag : Oncology & Rare Diseases

Revolution, Summit to Test RAS(ON) Drugs with Ivonescimab

STORM Therapeutics Names Dr. Eric Martin as Chief Development Officer

Innovent Presents Phase 3 DREAMS-1 Study of Mazdutide at ADA 85th

Simcere Zaiming Doses First US Patient in SIM0500 Phase 1 Trial

TFS HealthScience expands collaboration with Oncomatryx for OMTX705 trial

Simply Business Names Jeff Wright VP, Head of...

XCMG Opens 2026 Strong With Multiple Global Equipment...

Tamboran Appoints Todd Abbott as Chief Executive Officer

SchoolAI Research Counters AI Fears with 23,000 Teacher...

Edupoint Honors Five Districts in 2025 Synergy Awards

Quick Links

Stay up to date